MetaVia is trading 5.39% up at $1.84 in pre-market, based on the provided data, while the catalyst remains unclear.

  • No fresh company-specific announcement dated September 8, 2026, was identified in available reliable coverage.
  • The latest reported catalyst was its August 6 second-quarter update; July clinical-trial news and fourth-quarter data expectations appear dated rather than a clear explanation for this move.
  • Broader markets are mixed to weaker.